Clinical trials: Liver Tumour
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Safety and Efficacy Evaluation of Tremelimumab Plus Durvalumab(MEDI4736) in Combination with Concurrent Transarterial Chemoembolization in Unresectable Hepatocellular carcinoma
- Trial name
- NCT06911255
- Testing
- Tremelimumab Plus Durvalumab (MEDI4736), Transarterial chemoembolization (TACE)
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Yoon Jun Kim
Hepatocellular Carcinoma
Comparative Study of Carvedilol Monotherapy Versus Combination Therapy With Endoscopic Variceal Ligation (EVL) for Primary Prophylaxis of Variceal Bleeding in Patients With Hepatocellular Carcinoma With High-Risk Esophageal Varices
Esophageal varices are common in patients with hepatocellular carcinoma (HCC), with an incidence rate of 63% at the time of HCC diagnosis.
- Trial name
- NCT06836778
- Testing
- Carvedilol Tablets, Endoscopic Variceal Ligation
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatocellular Carcinoma, Hepatoblastoma
T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)
This study is for patients that have a type of cancer that arises from the liver, either called hepatocellular carcinoma or hepatoblastoma.
- Trial name
- NCT04093648
- Testing
- TEGAR T cells, Cytoxan, Fludarabine
- Sponsor
- Baylor College of Medicine
Liver Cancer, Pancreas Cancer
A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain
A prospective, multicenter, self-control clinical trial aim to enroll 110 patients suffered from upper abdominal (liver, pancreas, stomach, etc.) cancers .
- Conditions
- Liver Cancer, Pancreas Cancer, Stomach Cancer, Bile Duct Cancer
- Trial name
- NCT04014478
- Testing
- Endovascular Denervation
- Volunteers
- 110 people
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Hepatocellular Carcinoma, Liver Neoplasms
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death that ranks sixth in terms of incident cases, with an overall 5 years survival of 18%.
- Conditions
- Hepatocellular Carcinoma, Liver Neoplasms, Digestive System Neoplasms, Sorafenib
- Trial name
- NCT04518852
- Testing
- TACE combined with sorafenib and PD-1 mAb
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
HCC - Hepatocellular Carcinoma
Downstaging Prediction Model for HCC
This study is a real-world, single-center study that collects imaging and clinical data from patients with HCC who are downstaged beyond the UCSF criteria.
- Trial name
- NCT07058649
- Volunteers
- 369 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Lipid Profile
Hypoglycemic Potential of Garcinia Cambogia (Garcinia Gummi-gutta (L.) N.Robson) Rind Powder Among Pre-diebetic Obese Patients
Garcinia cambogia, rich in hydroxycitric acid (HCA), has been suggested to promote weight loss and improve metabolic parameters. Evidence regarding its efficacy in pre-diabetic obese adults remains limited.
- Trial name
- NCT07419074
- Testing
- Garcinia cambogia rind powder
- Where
- Pakistan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Lahore
Hepatocellular Carcinoma
Psychoeducational Intervention for Patients With Hepatocellular Carcinoma
This study aims to refine and pilot test HARMONY, a psychoeducational intervention for patients with newly diagnosed hepatocellular carcinoma (HCC).
- Trial name
- HARMONY (NCT06541990)
- Testing
- HARMONY, Enhanced usual care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Cancer, Hepatic, Cancer, Esophagus
Expectation, Pain Outcomes, and Pain Medication Following Oncology Abdominal Surgery: A Cohort Study
This study includes participants undergoing major hepatic surgery, surgery in the esophagus or stomach, or major surgery on the pancreas performed at Copenhagen University Hospital, Rigshospitalet.
- Conditions
- Cancer, Hepatic, Cancer, Esophagus, Cancer, Pancreas
- Trial name
- NCT07176052
- Testing
- cancer surgery
- Volunteers
- 200 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Primary or Metastatic Hepatic Adenocarcinoma
Cardiac Output Optimization on Postoperative Complications in Major Hepatic Surgery
Major hepatectomies are high-risk surgeries offered more and more frequently for the curative treatment of primary or secondary liver cancer, and for complex cases, representing a real challenge for medical teams.
- Trial name
- OPTILIVER (NCT04655885)
- Testing
- Optimization of cardiac flow by base water-electrolyte supply, Control arm
- Where
- France
- Volunteers
- 186 people
- Sponsor
- Institut Paoli-Calmettes
NAFLD (Nonalcoholic Fatty Liver Disease), Polycystic Ovarian Syndrome (PCOS)
PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease
To study the prevalence, non-invasive diagnostics and evolution of non-alcoholic-fatty-liver-disease (NAFLD) in patients with polycystic ovary syndrome (PCOS)
- Trial name
- P-CORIGA (NCT07146815)
- Testing
- FibroScan, MRI PDFF
- Where
- Belgium
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Ziekenhuis Oost-Limburg
Carcinoma, Hepatocellular
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
This study will look at whether our drug (sorafenib) in combination with chemotherapy delivered directly into your tumor using beads (DC Bead) will slow the progression of the disease.
- Trial name
- NCT00855218
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 107 sites in United States, Australia and 11 more
- Volunteers
- 307 people
- Sponsor
- Bayer
Cirrhosis, Cirrhosis Due to Hepatitis B
Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer
Aim: To use magnetic resonance imaging (MRI) scans without contrast to help improve diagnosis of liver cancer in people who are at increased risk of developing liver cancer.
- Conditions
- Cirrhosis, Cirrhosis Due to Hepatitis B, Cirrhosis and Chronic Liver Disease, Cirrhosis Due to Hepatitis C
- Trial name
- AMULET (NCT06658782)
- Testing
- non contrast enhanced MRI
- Where
- 2 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- University of Oxford
HCC - Hepatocellular Carcinoma
Sarcopenia and Systemic Therapy in HCC
This is a multi-center, retrospective observational study in patients with liver cancer (HCC) to assess the impact of sarcopenia (muscle loss) on the prognosis, duration, and tolerance of systemic treatment.
- Trial name
- Sarco HCC (NCT06805552)
- Where
- Italy
- Volunteers
- 270 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hepatocellular Carcinoma
SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma
This study is open to patients with primary HCC who cannot be treated by potentially curative treatment modalities, such as surgical resection, liver transplantation or percutaneous ablation.
- Trial name
- SIRTACE (NCT00867750)
- Testing
- Radioembolisation (SIR-Spheres® microspheres), Transarterial Chemoembolisation
- Where
- 2 sites in Germany, Spain
- Volunteers
- 28 people
- Sponsor
- Sirtex Medical
Hepatocellular Carcinoma
Study in Asia of the Combination of TACE With Sorafenib in HCC Patients
TACE possibly plays a significant role in contributing to a subgroup of surviving residual tumor tissue which is characterized by more aggressive biology.
- Trial name
- START (NCT00990860)
- Testing
- doxorubicin, TACE (Transcatheter arterial chemoembolization)
- Where
- 8 sites in Taiwan
- Volunteers
- 36 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Hepatocellular Carcinoma, Liver Cirrhosis
Radiofrequency Ablation With Gradual Radiofrequency Energy Increment for Hepatocellular Carcinoma Treatment
To evaluate local tumor progression rate at 12 months after percutaneous radiofrequency ablation with gradual radiofrequency energy delivery mode with Octopus electrodes in patients with hepatocellular carcinoma.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Chronic Liver Disease
- Trial name
- NCT05397860
- Testing
- Radiofrequency ablation using gradual radiofrequency energy delivery with Octopus electrodes
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)
The purpose of this study is to confirm that Ulinastatin is a safe and effective drug and it can reduce the incidence of postoperative hepatic failure in HCC patients.
- Trial name
- NCT01643447
- Testing
- Ulinastatin, Diammonium glycyrrhizinate
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Liver Cancer, Colorectal Cancer
The Inflammatory Response to Stress and Angiogenesis in Liver Resection
Patients with resectable liver metastases of colorectal origin will be assigned to laparoscopic liver resection or conventional open liver surgery. Blood samples will be drawn preoperatively and 24 hours after resection.
- Conditions
- Liver Cancer, Colorectal Cancer, Metastatic Cancer, Liver Metastases
- Trial name
- NCT03131778
- Testing
- Liver resection
- Volunteers
- 40 people
- Sponsor
- University Hospital, Ghent
Liver Cancer
Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
This prospective, single-center observational study evaluates the diagnostic accuracy of a novel Folate-targeted Near-Infrared II Carbon Dot (FA-CDots) probe for the ex vivo assessment of Hepatocellular Carcinoma (HCC).
- Trial name
- NCT07295340
- Testing
- Ex Vivo FA-CDots Staining
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.